CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 26 enrolled
Drug / intervention
Dextromethorphan +3 moredrug
Likely dose
Lidocaine 0mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02218203
NCT02218203Phase 2Completed

Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination (Factorial Design) Clinical Trial

Brigham and Women's Hospital·interventional·Posted Aug 18, 2014·Updated Dec 8, 2025

In Brief

A Phase 2 clinical trial evaluating Dextromethorphan, Lidocaine, and 2 other interventions for Central Neuropathic Pain and 2 related conditions. Completed, enrolled 26 participants across 1 site.

Detailed Summary

This randomized, placebo-controlled, double-blind 4x4 crossover clinical trial was part of a larger NIH-funded study to evaluate the analgesic efficacy of multiple dose-combinations of chronic oral (PO) dextromethorphan and intravenous (IV) lidocaine in central neuropathic pain following spinal cord injury.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 18, 2014
Enrollment StartApr 1, 2003
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 11.9 years ago

Interventions

Dextromethorphandrug

Administered in 4 periods (placebo, low dose, medium dose, and high dose) for each subject, relative to each subject's MTD)

Lidocainedrug

0mg, 1mg, 2mg, and 4mg Lidocaine per kg of lean body mass (LBM), during each of the 4 dextromethorphan periods (placebo, low dose, medium dose, and high dose)

Placebo (Dextromethorphan)drug

0mg Dextromethorphan

Placebo (Lidocaine)drug

0mg/kg LBM Lidocaine